Astrazeneca plc

AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines across four main therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease, with additional operations in Infectious Disease (Vaccines & Immune Therapies). The company's portfolio includes blockbuster oncology drugs such as Tagrisso (EGFR-mutant lung cancer), Imfinzi (immuno-oncology across lung, liver, bladder, and GI cancers), Lynparza (PARP inhibitor for breast and prostate cancers), Enhertu (HER2-targeted antibody-drug conjugate, partnered with Daiichi Sankyo), and Calquence (BTK inhibitor for blood cancers). In CVRM, Farxiga is a major SGLT2 inhibitor for diabetes, heart failure, and chronic kidney disease, though now facing generic competition. The Rare Disease unit, built on the Alexion acquisition, markets Ultomiris and Soliris for complement-mediated diseases and Strensiq for hypophosphatasia. AstraZeneca partners extensively with companies including Daiichi Sankyo (Enhertu, Datroway), Amgen (Tezspire), Sanofi (Beyfortus), and Merck (Lynparza). The company operates globally with significant revenue contributions from the United States (43%), Europe (22%), and Emerging Markets including China (27%). AstraZeneca is pursuing a target of $80 billion in Total Revenue by 2030, driven by new product launches, indication expansions, and a deep late-stage pipeline with more than 20 high-value readouts expected over the next 18 months. Updated Oct 7, 2026